ABBV-101

DRUG2 trials

Sponsors

AbbVie

Conditions

Healthy VolunteerHematologic Cancer

Phase 1

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Active, not recruitingNCT05753501

AbbVieHematologic Cancer

Start: 2023-06-09End: 2031-03-01Updated: 2026-08-06

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

CompletedNCT06887010

AbbVieHealthy Volunteer

Start: 2025-03-25End: 2025-09-16Updated: 2025-10-02

Related Papers

A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies.

Journal of Clinical Oncology2024-06-016 citations

Abstract 605: ABBV-101, a highly potent and selective clinical stage Bruton tyrosine kinase degrader, overcomes BTK mutation-induced resistance to BTK inhibitors

Cancer Research2024-03-22

Abbv-101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B-Cell Malignancies

Blood2023-11-027 citations